Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03049306 · ClinicalTrials.gov registry record · Phase 2
Propranolol for Sleep Apnea Therapy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03049306: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03049306 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03049306, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to test whether a beta blocker, propranolol, lowers the overnight heart rate sleep in obstructive sleep apnea (OSA) during CPAP withdrawal. The secondary objectives are to test whether propranolol influences sleep architecture, morning blood pressure, and vascular function including reactive hyperemia index (RHI) and a marker of arterial stiffness, augmentation index (AIX).
Interventions
- DRUG Placebo Oral Tablet
- DRUG Propranolol Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2024-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03049306
The ClinicalTrials.gov registry entry for NCT03049306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03049306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03049306 about?
NCT03049306 is a clinical study titled "Propranolol for Sleep Apnea Therapy". The primary objective of this study is to test whether a beta blocker, propranolol, lowers the overnight heart rate sleep in obstructive sleep apnea (OSA) during CPAP withdrawal. The secondary objectives are to test whether propranolol influences sleep architecture, morning blood pressure, and vascu...
What is the current status of trial NCT03049306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-02-15. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT03049306?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Propranolol Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03049306?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.